Sana Biotechnology to Present at Multiple Investor Conferences in September

SEATTLE, Sept. 01, 2026 /CourierPR/ -- Sana Biotechnology, a company focused on developing engineered cells as medical treatments, will present its business overview and updates at several prominent investor conferences in September 2026. The presentations, which are scheduled to take place at multiple conferences, aim to provide investors with insights into the company's progress and future plans.

On September 8, 2026, Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. Eastern Time. Following this, the company will present at Citi’s 2026 Biopharma Back-to-School Conference on September 10 at 1:40 p.m. ET. On September 14, Sana will deliver its presentation at the Morgan Stanley 24th Annual Global Healthcare Conference at 4:50 p.m. ET. Finally, the company will present at the HC Wainwright 28th Annual Global Investment Conference on September 15 at 11:30 a.m. ET.

Sana Biotechnology, based in Seattle, Washington; Cambridge, Massachusetts; and South San Francisco, California, is dedicated to advancing gene repair and cell replacement therapies to treat diseases. The company’s focus is on creating therapies that are broadly accessible to patients.

Sana’s presentations at these conferences will cover the company’s current research and development, as well as its strategic direction. “We are excited to share our latest advancements and progress with the investment community,” said a Sana spokesperson. “These conferences provide us with a valuable platform to discuss our vision and the potential of our therapies.”